ACTR6 CRISPR/Cas9 KO Plasmid (m): sc-426328
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ACTR6 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ACTR6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ACTR6 Antibody (G-8): sc-514988
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ACTR6 CRISPR/Cas9 KO Plasmid (m) | sc-426328 | 20 µg | $397.00 |
Overview
Actr6 encodes actin-related protein 6 (ACTR6), a nuclear actin-related factor that functions within chromatin regulatory complexes to support nucleosome remodeling and transcriptional control. ACTR6 activity contributes to the organization of promoter and enhancer architecture and influences DNA accessibility during processes such as replication stress responses and DNA damage repair. Through effects on chromatin dynamics, Actr6 can modulate cell-cycle progression, lineage specification, and genome stability programs. Dysregulated chromatin remodeling is broadly implicated in developmental abnormalities and oncogenic transcriptional states, making Actr6 a useful node for studying disease-relevant epigenetic mechanisms.
ACTR6 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Actr6 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Actr6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Actr6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ACTR6 protein expression.
This CRISPR knockout system enables efficient generation of Actr6-deficient cell models for investigation of ACTR6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Actr6 exon(s) critical for ACTR6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Actr6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ACTR6 CRISPR/Cas9 KO Plasmid (m) and ACTR6 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Actr6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ACTR6 HDR Plasmid (m) and ACTR6 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Actr6 homology arms to support homology-directed repair at defined Actr6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.